Salarius Pharmaceuticals, Inc. — Director's Dealing 2015

Jun 16, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2015-06-15

Reporting Person: Westphal Christoph H (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-15	Common Stock	P	284	$19.3733	Acquired	3906097	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2697264	Indirect

Footnotes

F1: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.

F2: Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.